Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
'
Interview with Andrew Mackie here:- https://www.goinpharma.com/en/new-antibiotic-therapies-what-future/ Link to more detailed presentation of Peprostat clinical trial results here:- http://www.ergomedplc.com/investor-relations/reports-presentations/
Nice write up here from Labiotech https://labiotech.eu/ergomed-peprostat-surgery/
Today's news takes the price to almost 215p, a price established in Feb 2017. Resistance is strong as it opened at 221p and sold off immediately. Let's see how the next few weeks pan out.
"Surgical bleeding is a common problem that can be associated with significant blood loss, increasing patient morbidity and mortality. PeproStat works fast and has shown to reduce the non-responder rate by almost 50% compared to a current standard of care product. This provides surgeons with a huge and clinically relevant advantage in providing better control of excess bleeding during surgery and could be hugely beneficial to patients" https://investegate.co.uk/ergomed-plc--ergo-/rns/ergomed-s-peprostat-reports-positive-results/201710230700042686U/ "
Ergomed Signs First Commercialisation Deal for Haemostatix Products - Deal driven by British innovation in the treatment of surgical bleeding with multi-million dollar potential Bodes well for PeproStat phase IIb trial results due in Q4 https://investegate.co.uk/ergomed-plc--ergo-/rns/commercialisation-deal-on-haemostatix-products/201709270700058982R/
FDA have finally lifted their hold on Cel-Sci's Multikine trial https://investegate.co.uk/ergomed-plc--ergo-/rns/fda-removal-of-hold-on-ph3-trial-with-multikine/201708141231019319N/
PeproStat trial now fully recruited - that was quick! It was only a month ago that we were advised they had reached mid-point in recruitment. Good stuff and now look forward to results in Q4. https://www.investegate.co.uk/ergomed-plc--ergo-/rns/recruitment-complete-early-for-phase-iib-study/201707240700068231L/
No problems and sorry to hear that. Hope they're OK now.
boomorbust - sincere apologies, I didn't make it to the presentations last night. Got off the tram at Old Trafford and got a call to head to A&E for a clumsy family member who needed stitches! Sorry. Am going to have a watch of the presentations when published online. You're right about this being a lonely place! Doesn't exactly stir interest for an outsider looking in.
Oh and welcome to the board!! As you can see it's a lonely place :)
Thanks very much for the offer - would just be interested in any feedback you have. Particularly your impressions of the new CEO (if he attends). Also any mention of potential new development partners. Hope you enjoy it and look forward to hearing your thoughts.
I’m heading to the presentation event at Old Trafford this evening. Have to confess that I’m not too familiar with this company, so will be listening and learning. Anything any long term holders or well-researched contributors on here would flag to me? Am happy to ask questions on behalf of any of you and will endeavour to live tweet (under the same username as on here) and even post to this board from the event.
Very positive RNS. PeproStat is 100% owned by Ergomed and is a coagulant, designed to stem bleeding during surgery. The current phase IIb is recruiting patients who are undergoing liver/soft tissue surgery, vascular surgery or spine surgery. It's administered during surgery on a sponge applied directly to the site of the bleed. Of course the trial is randomised and double blinded so nobody yet knows the outcome, however, would have thought that given the immediate nature of the application, it would become apparent very quickly if there were issues and surgeons would be reluctant to enrol patients to the trial. Just my opinion of course but the fact that recruitment is ahead of schedule and results will be released early is encouraging.
N+1 Singer have increased their target for Ergomed from 293 to 360. Zoptrex phase III results due from Aeterna Zentaris any day now.
"Ergomed, a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that on 3 April 2017, Mr Peter George, Chairman of the Company, bought 100,000 ordinary shares of 1p each in the Company ("Share(s)") at a price of 190p per Share." http://www.investegate.co.uk/ergomed-plc--ergo-/rns/director-pdmr-shareholding/201704041050015275B/
Strong set of results:- Revenue up 30% Gross profit up 43% to £12.0 million New contracts won in 2016 up 50% Strong backlog of £70 million contracted revenue Positive Phase II results for lorediplon Phase IIb study of PeproStat commenced Phase III results from Aeterna Zentaris' Zoptrex in endometrial cancer to be announced in April 2017
If you would like to hear management present the preliminary results for the year ended 31 December 2016 for Ergomed we will be hosting a webinar on Wednesday 29th March at 1:45pm. The presentation will last approximately 30 mins and there will then be an opportunity for Q&A. To join please register at: https://attendee.gotowebinar.com/register/5654169658073966851 If you would like to submit any questions for management ahead of the meeting please send them to hannah@equitydevelopment.co.uk Kind regards, The Equity Development Team
Phase IIb recruitment has now commenced in the UK for PeproStat (surgical bleeding) with top line results as early as Q1 2018. Thrombin is the current standard of care treatment for surgical bleeding but it has to be stored in powdered or frozen form and so must be either reconstituted or thawed before use - preparation time averages at 8 minutes which is not ideal when you have a patient bleeding on the operating table. The other option is to prepare in advance and throw away if it's not needed which is obviously costly and wasteful. PeproStat comes in liquid form and can be applied directly. Quick and convenient and a real advantage over SOC treatment - especially in a trauma situation. In early trials it demonstrated ultra rapid clotting action. Let's hope that is replicated in the study announced today. Have a feeling recruitment of first patient also generates a milestone payment to previous shareholders of Haemostatix. http://www.investegate.co.uk/ergomed-plc--ergo-/rns/initiates-phase-ii-study-of-topical-peprostat/201703200700058672Z/
Ergomed are attending Bio Europe - in Barcelona in March. They are listed as an investor so I guess on the look out for new co development opportunities. https://ebdgroup.knect365.com/bioeurope-spring/agenda/1
http://www.investegate.co.uk/ergomed-plc--ergo-/rns/modus-therapeutics-raises-sek-32-million/201702200700282443X/ Modus looks very promising. It was a spin out from the highly prestigious Karolinska Institutet and funded primarily by the Karolinska Development Fund. Sevuparin has Orphan Drug Status in both Europe and the US. Let's hope it lives up to its promise as Sickle Cell is a dreadfully painful disease with very poor treatment options.
Thanks, not sure whether you realise that I post under Bermudashorts over on ADVFN and it's good to see some activity on both boards. Think they did very well to negotiate double digit figures on the deal with Ferrer. I can understand why they don't reveal the exact figure and why they would consider it to be commercially sensitive information. Ergomed won't want future partners to know precise details of previous agreements as it may hamper negotiations and lead to unrealistic expectations.
P.S i think 10% is conservative ...it could be 12 , 13 , 14% the management has been quoted as saying " double digits " (if above 15% they probably would have said high double digits " i do not understand the evasiveness , why not disclosing the actual stake ?